Imperial College London
Alternate

ProfessorNicholasGrassly

Faculty of Medicine, School of Public Health

Prof of Infectious Disease & Vaccine Epidemiology
 
 
 
//

Contact

 

n.grassly Website

 
 
//

Location

 

1102Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Macklin:2019:10.1016/S1473-3099(19)30301-9,
author = {Macklin, GR and Grassly, NC and Sutter, RW and Mach, O and Bandyopadhyay, AS and Edmunds, WJ and O'Reilly, KM},
doi = {10.1016/S1473-3099(19)30301-9},
journal = {Lancet Infectious Diseases},
title = {Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.},
url = {http://dx.doi.org/10.1016/S1473-3099(19)30301-9},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: The eradication of wild and vaccine-derived poliovirus requires the global withdrawal of oral poliovirus vaccines (OPVs) and replacement with inactivated poliovirus vaccines (IPVs). The first phase of this effort was the withdrawal of the serotype 2 vaccine in April 2016, with a switch from trivalent OPVs to bivalent OPVs. The aim of our study was to produce comparative estimates of humoral and intestinal mucosal immunity associated with different routine immunisation schedules. METHODS: We did a random-effect meta-analysis with single proportions and a network meta-analysis in a Bayesian framework to synthesise direct and indirect data. We searched MEDLINE and the Cochrane Library Central Register of Controlled Trials for randomised controlled trials published from Jan 1, 1980, to Nov 1, 2018, comparing poliovirus immunisation schedules in a primary series. Only trials done outside western Europe or North America and without variation in age schedules (ie, age at administration of the vaccine) between study groups were included in the analyses, because trials in high-income settings differ in vaccine immunogenicity and schedules from other settings and to ensure consistency within the network of trials. Data were extracted directly from the published reports. We assessed seroconversion against poliovirus serotypes 1, 2, and 3, and intestinal immunity against serotype 2, measured by absence of shedding poliovirus after a challenge OPV dose. FINDINGS: We identified 437 unique studies; of them, 17 studies with a maximum of 8279 evaluable infants were eligible for assessment of humoral immunity, and eight studies with 4254 infants were eligible for intestinal immunity. For serotype 2, there was low between-trial heterogeneity in the data (τ=0·05, 95% credible interval [CrI] 0·009-0·15) and the risk ratio (RR) of seroconversion after three doses of bivalent OPVs was 0·14 (95% CrI 0·11-0·17) compared with three do
AU  - Macklin,GR
AU  - Grassly,NC
AU  - Sutter,RW
AU  - Mach,O
AU  - Bandyopadhyay,AS
AU  - Edmunds,WJ
AU  - O'Reilly,KM
DO  - 10.1016/S1473-3099(19)30301-9
PY  - 2019///
SN  - 1473-3099
TI  - Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.
T2  - Lancet Infectious Diseases
UR  - http://dx.doi.org/10.1016/S1473-3099(19)30301-9
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31350192
UR  - https://www.sciencedirect.com/science/article/pii/S1473309919303019?via%3Dihub
ER  -
Download